Sleep and geriatric psychopharmacology

Sleep Disorders: Diagnosis and Therapeutics

Volumn , Issue , 2008, Pages 163-172

  Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84988422908     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (147)

1. McCall WV. Diagnosis and management of insomnia in older people. J Am Geriatr Soc 2005; 53: S272-7.
2. Kamel NS, Gammack JK. Insomnia in the elderly: cause, approach, and treatment. Am J Med 2006; 119: 463-9.
3. Asplund R. Sleep disorders in the elderly. Drugs Aging 1999; 14: 91-103.
4. Voyer P, Verreault R, Mengue PN, Morin CM. Prevalence of insomnia and its associated factors in elderly long-term care residents. Arch Gerontol Geriatr 2006; 42: 1-20.
5. Nau SD, McCrae CS, Cook KG, Lichstein KL. Treatment of insomnia in older adults. Clin Psychol Rev 2005; 25: 645-72.
6. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry 1985; 42: 225-32.
7. Drake CL, Roehrs T, Roth T. Insomnia causes, consequences, and therapeutics: an overview. Depress Anxiety 2003; 18:163-76.
8. Bliwise DL. Sleep in normal aging and dementia. Sleep 1993; 16: 40-81.
9. Hornung OP, Danker-Hopfe H, Heuser I. Age-related changes in sleep and memory: commonalities and interrelationships. Exp Gerontol 2005; 40: 279-85.
10. Thase ME. Correlates and consequences of chronic insomnia. Gen Hosp Psychiatry 2005; 27: 100-12.
11. Sateia MJ, Nowell PD. Insomnia. Lancet 2004; 364: 1959-73.
12. Gooneratne NS, Weaver TE, Cater JR et al. Functional outcomes of excessive daytime sleepiness in older adults. J Am Geriatr Soc 2003; 51: 642-9.
13. Mendelson WB, Roth T, Cassella J et al. The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium. Sleep Med Rev 2004; 8: 7-17.
14. Conn DK, Madan R. Use of sleep-promoting medications in nursing home residents: risks versus benefits. Drugs Aging 2006; 23: 271-87.
15. Morlock RJ, Tan M, Mitchell DY. Patient characteristics and patterns of drug use for sleep complaints in the United States:analysis of National Ambulatory Medical Survey data, 1997-2002. Clin Ther 2006; 28: 1044-53.
16. Egan M, Moride Y, Wolfson C, Monette J. Long-term continuous use of benzodiazepines by older adults in Quebec:prevalence, incidence and risk factors. J Am Geriatr Soc 2000; 48: 811-16.
17. Greenblatt DJ. Pharmacology of benzodiazepine hypnotics. J Clin Psychiatry 1992; 53(No. 6 Suppl): 7-13.
18. Greenblatt DJ. Benzodiazepine hypnotics: sorting the pharmacokinetic facts. J Clin Psychiatry 1991; 52(Sept Suppl):4-10.
19. Greenblatt DJ, Miller LG, Shader RI. Neurochemical and pharmacokinetic correlates of the clinical action of benzodiazepine hypnotic drugs. Am J Med 1990; 88(Suppl 3A):18S-24S.
20. Greenblatt DJ, Divoll M, Abernethy DR, Shader RI. Benzodiazepine hypnotics: kinetic and therapeutic options. Sleep 1982; 5(Suppl 1): S18-27.
21. Greenblatt DJ, Divoll M, Abernethy DR, Ochs HR, Shader RI. Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics. Drug Metab Rev 1983; 14: 251-92.
22. Panneman MJ, Goettsch WG, Kramarz P, Herings RM. The costs of benzodiazepine-associated hospital-treated fall injuries in the EU: a Pharmo study. Drugs Aging 2003; 20:833-9.
23. Cumming RG, Le Couteur DG. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs 2003; 17: 825-37.
24. Sorock GS, Shimkin EE. Benzodiazepine sedatives and the risk of falling in a community-dwelling elderly cohort. Arch Intern Med 1988; 148: 2441-4.
25. Ray WA, Fought RL, Decker MD. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol 1992; 136: 873-83.
26. Ray WA. Psychotropic drugs and injuries among the elderly:a review. J Clin Psychopharmacol 1992; 12: 386-96.
27. Barbone F, McMahon AD, Davey PG et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998; 352: 1331-6.
28. Campbell AJ. Drug treatment as a cause of falls in old age: a review of the offending agents. Drugs Aging 1991; 1: 289-302.
29. Cumming RG. Epidemiology of medication-related falls and fractures in the elderly. Drugs Aging 1998; 12: 43-53.
30. Greenblatt DJ, Harmatz JS, Zinny MA, Shader RI. Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. N Engl J Med 1987; 317: 722-8.
31. Mitler MM, Seidel WF, van den Hoed J, Greenblatt DJ, Dement WC. Comparative hypnotic effects of flurazepam, triazolam, and placebo: a long-term simultaneous nighttime and daytime study. J Clin Psychopharmacol 1984; 4: 2-13.
32. Bliwise D, Seidel W, Greenblatt DJ, Dement W. Nighttime and daytime efficacy of flurazepam and oxazepam in chronic insomnia. Am J Psychiatry 1984; 141: 191-5.
33. A receptor function. J Pharmacol Exp Ther 1988; 246: 170-6.
34. Ochs HR, Greenblatt DJ, Eckardt B, Harmatz JS, Shader RI. Repeated diazepam dosing in cirrhotic patients: cumulation and sedation. Clin Pharmacol Ther 1983; 33: 471-6.
35. Neutel I. Benzodiazepine-related traffic accidents in young and elderly drivers. Hum Psychopharmacol Clin Exp 1998; 13: S115-23.
36. Landi F, Cesari M, Russo A et al. Benzodiazepines and the risk of urinary incontinence in frail older persons living in the community. Clin Pharmacol Ther 2002; 72: 729-34.
37. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989; 262: 3303-7.
38. Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ 3rd. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316: 363-9.
39. Hemmelgarn B, Suissa S, Huang A, Boivin JF, Pinard G. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA 1997; 278: 27-31.
40. Gray SL, LaCroix AZ, Hanlon JT et al. Benzodiazepine use and physical disability in community-dwelling older adults. J Am Geriatr Soc 2006; 54: 224-30.
41. Tamblyn R, Abrahamowicz M, du Berger R, McLeod P, Bartlett G. A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. J Am Geriatr Soc 2005; 53: 233-41.
42. Ensrud KE, Blackwell TL, Mangione CM et al. Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc 2002; 50: 1629-37.
43. Hanlon JT, Horner RD, Schmader KE et al. Benzodiazepine use and cognitive function among community-dwelling elderly. Clin Pharmacol Ther 1998; 64: 684-92.
44. Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry 2001; 158: 892-8.
45. Herings RMC, Stricker BHC, de Boer A, Bakker A, Sturmans F. Benzodiazepines and the risk of falling leading to femur fractures. Arch Intern Med 1995; 155: 1801-7.
46. Larson EB, Kukull WA, Buchner D, Reifler BV. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med 1987; 107: 169-73.
47. Beyth RJ, Shorr RI. Epidemiology of adverse drug reactions in the elderly by drug class. Drugs Aging 1999; 14: 231-9.
48. Routledge PA, O’Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol 2004; 57:121-6.
49. Gurwitz JH, Avorn J. The ambiguous relation between aging and adverse drug reactions. Ann Intern Med 1991; 114:956-66.
50. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokin 2005; 44: 33-60.
51. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly: therapeutic considerations. Clin Pharmacokin 1991; 21: 165-77, 262-73.
52. Greenblatt DJ, Sellers EM, Shader RI. Drug disposition in old age. N Engl J Med 1982; 306: 1081-8.
53. Hämmerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly: clinical implications. Clin Pharmacokin 1998; 35: 49-64.
54. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004; 56: 163-84.
55. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004; 57: 6-14.
56. Kinirons MT, Crome P. Clinical pharmacokinetic considerations in the elderly. An update. Clin Pharmacokin 1997; 33: 302-12.
57. Barnhill JG, Greenblatt DJ, Miller LG et al. Kinetic and dynamic components of increased benzodiazepine sensitivity in aging animals. J Pharmacol Exp Ther 1990; 253: 1153-61.
58. Guthrie S, Cooper RL, Thurman R, Linnoila M. Pharmacody - namics and pharmacokinetics of ethanol, diazepam and pentobarbital in young and aged rats. Pharmacol Toxicol 1987; 61: 308-12.
59. Wilkinson GR. Clearance approaches in pharmacology. Pharmacol Rev 1987; 39: 1-47.
60. Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975; 18: 377-90.
61. Greenblatt DJ. Presystemic extraction: mechanisms and consequences. J Clin Pharmacol 1993; 33: 650-6.
62. Greenblatt DJ, von Moltke LL, Shader RI. The importance of presystemic extraction in clinical psychopharmacology. J Clin Psychopharmacol 1996; 16: 417-19.
63. Matthew H, Proudfoot AT, Aitken RC, Raeburn JA, Wright N. Nitrazepam - a safe hypnotic. BMJ 1969; 3: 23-5.
64. Greenblatt DJ, Allen MD, Noel BJ, Shader RI. Acute overdosage with benzodiazepine derivative. Clin Pharmacol Ther 1977; 21: 497-514.
65. Holm V, Melander A, Wåhlin-Boll E. Influence of food and of age on nitrazepam kinetics. Drug Nutr Interact 1982; 1:307-11.
66. Jochemsen R, Hogendoorn JJ, Dingemanse J et al. Pharma - cokinetics and bioavailability of intravenous, oral, and rectal nitrazepam in humans. J Pharmacokinet Biopharm 1982; 10:231-45.
67. Jochemsen R, van der Graaf M, Boejinga J, Breimer D. Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. Br J Clin Pharmacol 1982; 13:319-24.
68. Jochemsen R, van Boxtel CJ, Hermans J, Breimer DD. Kinetics of five benzodiazepine hypnotics in healthy subjects. Clin Pharmacol Ther 1983; 34: 42-7.
69. Kangas L, Iisalo E, Kanto J et al. Human pharmacokinetics of nitrazepam: effect of age and diseases. Eur J Clin Pharmacol 1979; 15: 163-70.
70. Greenblatt DJ, Abernethy DR, Locniskar A et al. Age, sex, and nitrazepam kinetics: relation to antipyrine disposition. Clin Pharmacol Ther 1985; 38: 697-703.
71. Castleden CM, George CF, Marcer D, Hallett C. Increased sensitivity to nitrazepam in old age. BMJ 1977; 1: 10-12.
72. Greenblatt DJ, Allen MD. Toxicity of nitrazepam in the elderly: a report from the Boston Collaborative Drug Surveillance Program. Br J Clin Pharmacol 1978; 5: 407-13.
73. Greenblatt DJ, Shader RI, Koch-Weser J. Flurazepam hydrochloride. Clin Pharmacol Ther 1975; 17: 1-14.
74. Greenblatt DJ, Shader RI, Koch-Weser J. Flurazepam hydrochloride, a benzodiazepine hypnotic. Ann Intern Med 1975; 83: 237-41.
75. Miller LG, Greenblatt DJ, Abernethy DR et al. Kinetics, brain uptake, and receptor binding characteristics of flurazepam and its metabolites. Psychopharmacology 1988; 94: 386-91.
76. Greenblatt DJ, Harmatz JS, Engelhardt N, Shader RI. Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics: flurazepam, temazepam, and triazolam. Arch Gen Psychiatry 1989; 46: 326-32.
77. Greenblatt DJ, Divoll M, Harmatz JS, MacLaughlin DS, Shader RI. Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. Clin Pharmacol Ther 1981; 30:475-86.
78. Greenblatt DJ, Allen MD, Shader RI. Toxicity of high-dose flurazepam in the elderly. Clin Pharmacol Ther 1977; 21:355-61.
79. Hilbert JM, Chung M, Radwanski E et al. Quazepam kinetics in the elderly. Clin Pharmacol Ther 1984; 36: 566-9.
80. Locniskar A, Greenblatt DJ. Oxidative versus conjugative biotransformation of temazepam. Biopharm Drug Dispos 1990; 11: 499-506.
81. Divoll M, Greenblatt DJ, Harmatz JS, Shader RI. Effect of age and gender on disposition of temazepam. J Pharm Sci 1981; 70: 1104-7.
82. Ochs HR, Greenblatt DJ, Heuer H. Is temazepam an accumulating hypnotic? J Clin Pharmacol 1984; 24: 58-64.
83. Friedman H, Greenblatt DJ, Burstein ES et al. Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. J Clin Pharmacol 1988; 28: 228-33.
84. Friedman H, Greenblatt DJ, Burstein ES, Harmatz JS, Shader RI. Population study of triazolam pharmacokinetics. Br J Clin Pharmacol 1986; 22: 639-42.
85. Greenblatt DJ, Shader RI, Divoll M, Harmatz JS. Adverse reactions to triazolam, flurazepam, and placebo in controlled clinical trials. J Clin Psychiatry 1984; 45: 192-5.
86. von Moltke LL, Greenblatt DJ, Harmatz JS et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996; 276: 370-9.
87. Perloff MD, von Moltke LL, Court MH et al. Midazolam and triazolam biotransformation in mouse and human liver microsomes:relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ther 2000; 292: 618-28.
88. Greenblatt DJ, Harmatz JS, Shapiro L et al. Sensitivity to triazolam in the elderly. N Engl J Med 1991; 324: 1691-8.
89. Greenblatt DJ, Divoll M, Abernethy DR et al. Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity. Br J Clin Pharmacol 1983; 15: 303-9.
90. Smith RB, Divoll M, Gillespie WR, Greenblatt DJ. Effect of subject age and gender on the pharmacokinetics of oral triazolam and temazepam. J Clin Psychopharmacol 1983; 3: 172-6.
91. Greenblatt DJ, Harmatz JS, von Moltke LL, Wright CE, Shader RI. Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin Pharmacol Ther 2004; 76: 467-79.
92. Robin DW, Hasan SS, Edeki T et al. Increased baseline sway contributes to increased losses of balance in older people following triazolam. J Am Geriatr Soc 1996; 44: 300-4.
93. Jonas JM. Idiosyncratic side effects of short half-life benzodiazepine hypnotics: fact or fancy? Hum Psychopharmacol 1992; 7: 205-16.
94. Lasagna L. The Halcion story: trial by media. Lancet 1980; 1:815-16.
95. Institute of Medicine. Halcion: An Independent Assessment of Safety and Risk. Washington, DC: National Academy Press, 1997.
96. Korpi ER, Mattila MJ, Wisden W, Lüddens H. GABAA-receptor subtypes: clinical efficacy and selectivity of benzodiazepine site ligands. Ann Med 1997; 29: 275-82.
97. Byrnes JJ, Greenblatt DJ, Miller LG. Benzodiazepine receptor binding of non-benzodiazepines in vivo: alpidem, zolpidem, and zopiclone. Brain Res Bull 1992; 29: 905-8.
98. Sanger DJ, Benavides J, Perrault G et al. Recent developments in the behavioral pharmacology of benzodiazepine (omega) receptors: evidence for the functional significance of receptor subtypes. Neurosci Biobehav Rev 1994; 18: 355-72.
99. Sanna E, Busonero F, Talani G et al. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes. Eur J Pharmacol 2002; 451: 103-10.
100. Möhler H. GABAA receptor diversity and pharmacology. Cell Tissue Res 2006; 326: 505-16.
101. Ebert B, Wafford KA, Deacon S. Treating insomnia: current and investigational pharmacological approaches. Pharmacol Ther 2006; 112: 612-29.
102. Darcourt G, Pringuey D, Sallière D, Lavoisy J. The safety and tolerability of zolpidem: an update. J Psychopharmacol 1999; 13: 81-93.
103. Harrison TS, Keating GM. Zolpidem: a review of its use in the management of insomnia. CNS Drugs 2005; 19: 65-89.
104. Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000; 59: 865-89.
105. von Moltke LL, Greenblatt DJ, Granda BW et al. Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Pharmacol 1999; 48: 89-97.
106. Greenblatt DJ, Harmatz JS, von Moltke LL et al. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. J Pharmacol Exp Ther 2000; 293: 435-43.
107. Greenblatt DJ, Harmatz JS, von Moltke LL et al. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther 1998; 64: 553-61.
108. Greenblatt DJ, von Moltke LL, Harmatz JS et al. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. Clin Pharmacol Ther 1998; 64:661-71.
109. Olubodun JO, Ochs HR, Trüten V et al. Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use. J Clin Pharmacol 2002; 42: 1142-6.
110. Olubodun JO, Ochs HR, von Moltke LL et al. Pharma - cokinetic properties of zolpidem in elderly and young adults:possible modulation by testosterone in men. Br J Clin Pharmacol 2003; 56: 297-304.
111. Barkin RL. Zolpidem extended-release: a single insomnia treatment option for sleep induction and sleep maintenance symptoms. Am J Ther 2007; 14: 299-305.
112. Weinling E, McDougall S, Andre F, Bianchetti G, Dubruc C. Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance. Fundam Clin Pharmacol 2006; 20: 397-403.
113. Greenblatt DJ, Legangneux E, Harmatz JS et al. Dynamics and kinetics of a modified-release formulation of zolpidem:comparison with immediate-release standard zolpidem and placebo. J Clin Pharmacol 2006; 46: 1469-80.
114. Melton ST, Wood JM, Kirkwood CK. Eszopiclone for insomnia. Ann Pharmacother 2005; 39: 1659-66.
115. Najib J. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther 2006; 28: 491-516.
116. Becquemont L, Mouajjah S, Escaffre O et al. Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Drug Metab Dispos 1999; 27: 1068-73.
117. Fernandez C, Maradeix V, Gimenez F, Thuillier A, Farinotti R. Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. Drug Metab Dispos 1993; 21: 1125-8.
118. Sanger DJ, Morel E, Perrault G. Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem. Eur J Pharmacol 1996; 313: 35-42.
119. Noguchi H, Kitazumi K, Mori M, Shiba T. Binding and neuropharmacological profile of zaleplon, a novel nonbenzodiazepine sedative/hypnotic. Eur J Pharmacol 2002; 434: 21-8.
120. Barbera J, Shapiro C. Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Saf 2005; 28: 301-18.
121. Patat A, Paty I, Hindmarch I. Pharmacodynamic profile of zaleplon, a new non-benzodiazepine hypnotic agent. Hum Psychopharmacol 2001; 16: 369-92.
122. Dooley M, Plosker GL. Zaleplon: a review of its use in the treatment of insomnia. Drugs 2000; 60: 413-45.
123. Hurst M, Noble S. Zaleplon. CNS Drugs 1999; 11: 387-92.
124. Rosen AS, Fournié P, Darwish M, Danjou P, Troy SM. Zaleplon pharmacokinetics and absolute bioavailability. Biopharm Drug Dispos 1999; 20: 171-5.
125. Lake BG, Ball SE, Kao J et al. Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica 2002; 32: 835-47.
126. Renwick AB, Mistry H, Ball SE et al. Metabolism of zaleplon by human hepatic microsomal cytochrome P450 isoforms. Xenobiotica 1998; 28: 337-48.
127. Zlotos DP. Recent advances in melatonin receptor ligands. Arch Pharm (Weinheim) 2005; 338: 229-47.
128. Kato K, Hirai K, Nishiyama K et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005; 48: 301-10.
129. Wurtman R. Ramelteon: a novel treatment for the treatment of insomnia. Expert Rev Neurother 2006; 6: 957-64.
130. Karim A, Tolbert D, Cao C. Disposition kinetics and tolerance of escalating single doses of Ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol 2006; 46: 140-8.
131. Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 2006; 63: 1149-57.
132. Greenblatt DJ, Harmatz JS, Karim A. Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J Clin Pharmacol 2007; 47: 485-96.
133. Georgotas A, Forsell TL, Mann JJ, Kim M, Gershon S. Trazodone hydrochloride: a wide spectrum antidepressant with a unique pharmacological profile. A review of its neurochemical effects, pharmacology, clinical efficacy, and toxicology. Pharmacotherapy 1982; 2: 255-65.
134. Brogden RN, Heel RC, Speight TM, Avery GS. Trazodone: a review of its pharmacological properties and therapeutic use in depression and anxiety. Drugs 1981; 21: 401-29.
135. James SP, Mendelson WB. The use of trazodone as a hypnotic:a critical review. J Clin Psychiatry 2004; 65: 752-5.
136. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005; 66:469-76.
137. Venkatakrishnan K, von Moltke LL, Court MH et al. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 2000; 28: 1493-504.
138. Zalma A, von Moltke LL, Granda BW et al. In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. Biol Psychiatry 2000; 47: 655-61.
139. Rotzinger S, Fang J, Baker GB. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos 1998; 26: 572-5.
140. Greenblatt DJ, Friedman H, Burstein ES et al. Trazodone kinetics: effect of age, gender, and obesity. Clin Pharmacol Ther 1987; 42: 193-200.
141. Bayer AJ, Pathy MS, Ankier SI. Pharmacokinetic and pharmacodynamic characteristics of trazodone in the elderly. Br J Clin Pharmacol 1983; 16: 371-6.
142. Blyden GT, Greenblatt DJ, Scavone JM, Shader RI. Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration. J Clin Pharmacol 1986; 26: 529-33.
143. Scavone JM, Greenblatt DJ, Harmatz JS, Engelhardt N, Shader RI. Pharmacokinetics and pharmacodynamics of diphenhydramine 25 mg in young and elderly volunteers. J Clin Pharmacol 1998; 38: 603-9.
144. Berlinger WG, Goldberg MJ, Spector R, Chiang CK, Ghoneim M. Diphenhydramine: kinetics and psychomotor effects in elderly women. Clin Pharmacol Ther 1982; 32: 387-91.
145. Simons KJ, Watson WT, Martin TJ, Chen XY, Simons FE. Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children. J Clin Pharmacol 1990; 30: 665-71.
146. Borbély AA, Youmbi-Balderer G. Effect of diphenhydramine on subjective sleep parameters and on motor activity during bedtime. Int J Clin Pharmacol Ther Toxicol 1988; 26: 392-6.
147. Roehrs TA, Tietz EI, Zorick FJ, Roth T. Daytime sleepiness and antihistamines. Sleep 1984; 7: 137-41.